InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

- Current share price for OCC : $0.730

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$199 Orthocell Extends Distributor Network in the EU 8 May 2018 9:14AM $0.345 $0.730 risen by 111.59%
$199 Results of Meeting 7 May 2018 5:16PM $0.345 $0.730 risen by 111.59%
$199 Orthocell Announces Successful Bone Repair Study Results 1 May 2018 9:10AM $0.315 $0.730 risen by 131.75%
$199 Appendix 4C - quarterly 30 Apr 2018 6:14PM $0.315 $0.730 risen by 131.75%
$199 Orthocell Appoints First Distributor in the EU 30 Apr 2018 8:25AM $0.305 $0.730 risen by 139.34%
$199 Updated Investor Presentation 16 Apr 2018 8:25AM $0.300 $0.730 risen by 143.33%
$199 Investor Update 9 Apr 2018 6:45PM $0.305 $0.730 risen by 139.34%
$199 Notice of General Meeting/Proxy Form 6 Apr 2018 4:19PM $0.295 $0.730 risen by 147.46%
$199 Cedrus Investments Initiation of Coverage 4 Apr 2018 1:41PM $0.290 $0.730 risen by 151.72%
$199 Prof. Giuseppe Luongo Appointed to Orthocell Advisory Board 26 Mar 2018 8:26AM $0.315 $0.730 risen by 131.75%
$199 NDF Research Initiation of Coverage 20 Mar 2018 8:20AM $0.290 $0.730 risen by 151.72%
$199 Prof. Massimo Simion Appointed to Orthocell Advisory Board 19 Mar 2018 8:21AM $0.290 $0.730 risen by 151.72%
$199 FDA Publication Supports Regenerative Medicine Acceleration 15 Mar 2018 9:49AM $0.290 $0.730 risen by 151.72%
$199 Half Yearly Report and Accounts 23 Feb 2018 7:33PM $0.330 $0.730 risen by 121.21%
$199 New Cell Factory Patent Granted in the US 22 Feb 2018 9:57AM $0.320 $0.730 risen by 128.13%
$199 Positive CelGro Study Results in ACL Reconstruction 5 Feb 2018 9:58AM $0.350 $0.730 risen by 108.57%
$199 Appendix 4C - quarterly 31 Jan 2018 7:12PM $0.350 $0.730 risen by 108.57%
$199 Orthocell Granted Canadian Tendon Regeneration Patent 31 Jan 2018 10:10AM $0.350 $0.730 risen by 108.57%
$199 Change in substantial holding MHZ 30 Jan 2018 8:21AM $0.345 $0.730 risen by 111.59%
$199 Change in substantial holding PA 19 Jan 2018 11:29AM $0.340 $0.730 risen by 114.71%
$199 Change in substantial holding SRV 19 Jan 2018 11:27AM $0.340 $0.730 risen by 114.71%
$199 Change in substantial holding MC 19 Jan 2018 11:26AM $0.340 $0.730 risen by 114.71%
$199 Change in substantial holding QXZ 19 Jan 2018 11:25AM $0.340 $0.730 risen by 114.71%
$199 New Patent for Suture-Less Repair of Soft Tissue Secured 18 Jan 2018 9:56AM $0.335 $0.730 risen by 117.91%
$199 Successful Completion of Share Purchase Plan 12 Jan 2018 11:36AM $0.345 $0.730 risen by 111.59%

576 - 600 of 760 results

Page 24 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.